Hormonal Treatment of Pancreatic Cancer
Author Information
Author(s): P.A. Philip, J. Carmichael, K. Tonkin, P.K. Buamah, J. Britton, M. Dowsett, A.L. Harris
Primary Institution: ICRF Clinical Oncology Unit, Churchill Hospital, Oxford, UK
Hypothesis
Does the combination of goserelin and hydrocortisone improve outcomes in patients with pancreatic carcinoma?
Conclusion
The study found that goserelin combined with hydrocortisone did not show an effective anti-tumor response in pancreatic carcinoma patients.
Supporting Evidence
- Goserelin did not result in any objective remission in disease sites.
- Median survival duration was 5 months for all patients.
- Significant reductions in hormone levels were observed, but no corresponding tumor response.
Takeaway
Doctors tried a new hormone treatment for pancreatic cancer, but it didn't help the patients get better.
Methodology
Eighteen patients with advanced pancreatic cancer were treated with goserelin and hydrocortisone, and their hormone levels and tumor markers were monitored.
Limitations
The study had a small sample size and no objective tumor response was observed.
Participant Demographics
11 males and 7 females, median age 61.5 years, all naive to chemotherapy and radiotherapy.
Statistical Information
P-Value
0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website